2. Search Result
Search Result
Results for "

female stress incontinence

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1711
    Norfenefrine

    		Adrenergic Receptor Endocrinology
    Norfenefrine is an orally active, endogenously found α-adrenergic agonist and can be used for the research of female stress incontinence .
    Norfenefrine
  • HY-B1711A
    Norfenefrine hydrochloride

    		Adrenergic Receptor Endocrinology
    Norfenefrine hydrochloride is an orally active, endogenously found α-adrenergic agonist and can be used for the research of female stress incontinence .
    Norfenefrine hydrochloride
  • HY-B1711AR
    Norfenefrine (hydrochloride) (Standard)

    		Adrenergic Receptor Endocrinology
    Norfenefrine (hydrochloride) (Standard) is the analytical standard of Norfenefrine (hydrochloride). This product is intended for research and analytical applications. Norfenefrine hydrochloride is an orally active, endogenously found α-adrenergic agonist and can be used for the research of female stress incontinence .
    Norfenefrine (hydrochloride) (Standard)
  • HY-137055
    PF-3774076

    		Others Others
    PF-3774076 is a highly central nervous system (CNS) penetrant, potent, and selective human α1A-adrenoceptor partial agonist. It exhibits good potency and selectivity in multiple binding and functional assays. PF-3774076 increases peak urethral pressure in anesthetized female dogs in a dose-dependent manner via a central mechanism. PF-3774076 affects both the proximal and distal portions of the urethra in vivo. These properties suggest that PF-3774076 may have significant benefit in the treatment of stress urinary incontinence (SUI) as a CNS-penetrant α1A receptor partial agonist. However, despite its partial agonism and selectivity for α1A receptors, PF-3774076 failed to provide adequate safety differences in in vivo models of cardiovascular function. This may be due to the simultaneous activation of both peripheral and central α1A receptors. These data suggest that while central α1A partial agonists may have significant benefit in the treatment of SUI, this class of agents may have difficulty achieving the desired urethral selectivity without affecting cardiovascular function.
    PF-3774076

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: